We have two price target areas for this biopharmaceutical firm.
An oncology and a oil & gas concern, new names on my list, have my attention.
Let's check the charts on this clinical stage drug developer.
These names are off to good starts to 2023 and could have more room to run.
Let's check the charts and indicators.
There are signs that M&A deal activity will pick up in the sector after a couple of subpar years.
Industry experts share their favorite biotech plays for this year.
The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.
Let's dip into the biotech mailbag as the year comes to an end.
Here's what traders should wait for.